Diabetes and CVD module 4: the role of SGLT2 inhibitors

Released10 February 2021     Expires: 10 February 2023      Programme: Diabetes and CVD 1 CPD/CME credit

Sponsorship Statement: Novo Nordisk have provided sponsorship to support the development of this e-learning programme. Novo Nordisk have had no input into the content of this programme.

Designed to give healthcare professionals an understanding of the outcomes trials with SGLT2 inhibitors in patients with diabetes, chronic kidney diease and heart failure. It is one of several modules in our diabetes and CVD programme.

Advertisement
Heart failure - BJC Learning programme
For healthcare professionals only

Learning objectives

After completing this module, participants should be able to:

  • Review the results of cardiovascular outcome trials (CVOTs) with SGLT2 inhibitors in people with diabetes, including EMPA-REG OUTCOME, CANVAS and DECLARE-TIMI 58
  • Asses the results of trials of SGLT2 inhibitors in patients with renal disease, including CREDENCE and DAPA-CKD
  • Asses the results of trials of SGLT2 inhibitors in patients with heart failure, including DAPA-HF and EMPEROR-Reduced
  • Define patients who would benefit from treatment with SGLT2 inhibitors

Faculty

Professor Miles Fisher, Honorary Professor, University of Glasgow, Glasgow

Accreditation

1 CPD/CME credit, 1 hour
BJC Learning has assigned 1 hour of CPD/CME credit to this module

You need to login to take this module

You need to be a registered member to view this page. It's quick, free and offers you a host of other benefits, including the facility to print and download articles and supplements, access our archived issues and receive email updates when new issues and other content are online.

11 thoughts on “Diabetes and CVD module 4: the role of SGLT2 inhibitors”

All rights reserved. No part of this programme may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers, Medinews (Cardiology) Limited.

It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs becomes necessary. The editors/authors/contributors and the publishers have taken care to ensure that the information given in this text is accurate and up to date. Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice.

Healthcare professionals should consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.